GLP-1s and antidepressants: what the label says

The short answer, before anything else

Neither label names a single antidepressant. Not sertraline, not fluoxetine, not any of them. I read both prescribing informations rather than repeat what circulates.

That is not the same as "safe". It means nobody has published the study, so the honest answer is that this specific pairing has not been tested — and that is worth knowing before you go looking for a warning that does not exist.

What the labels do say

Both medicines slow the stomach down, and both labels turn that into the same general caution.

Wegovy says it delays gastric emptying and may affect the absorption of oral medicines taken alongside it. It asks for extra clinical or laboratory monitoring for oral medicines with a narrow therapeutic index, or that need monitoring anyway¹. Zepbound says the same, and names warfarin as its example².

Now the part that surprised me. In its own clinical pharmacology section, the Wegovy label reports that in interaction trials of the once-weekly injection, semaglutide did not affect the absorption of the oral drugs tested¹.

The drugs tested were levothyroxine, warfarin, metformin, digoxin, lisinopril, ethinyl estradiol, levonorgestrel, furosemide, rosuvastatin and omeprazole¹. Not one antidepressant on that list. So the silence is real, and it is a gap rather than a clearance.

Common antidepressants are not narrow-therapeutic-index medicines, which is the category the label singles out. Lithium is, so is warfarin — if either is in your cabinet, that sentence is about you.

Why so many of us are asking

Because the two live together far more often than people assume.

A Norwegian registry study looked at everyone who started a weight-loss medicine in 2023 and 2024 and compared them with five matched controls each. Among the people starting, 20% to 24% had been dispensed an antidepressant in the previous year. Among controls it was 10% to 11%³. That is 150,036 people starting semaglutide alone.

There is a second reason, and it is fair to name it. In a UK cohort of 294,719 adults followed for a decade, new episodes of gaining 5% or more of body weight ran at 11.2 per 100 person-years in people prescribed antidepressants against 8.1 in people who were not⁴. The authors are careful to say the association may not be causal. Still, a lot of women arrive at a GLP-1 through exactly that door.

The mood warning that came off the label this year

If you remember a suicidality warning on these medicines, your memory is correct — and out of date.

Both labels now list Suicidal Behavior and Ideation as removed, in February 2026¹². There is no such section left in either document.

The evidence that accumulated underneath that change is unusually large. A meta-analysis of 80 randomised placebo-controlled trials covering 107,860 patients found no significant difference against placebo in serious psychiatric adverse events, in non-serious ones, or in change in depressive symptoms⁵. A cohort of 240,618 patients with overweight or obesity found a lower risk of a new episode of suicidal ideation on semaglutide than on other weight-loss medicines⁶.

That is a population-level answer to a population-level worry. It is not a promise about you, and it does not mean a mood change on a new medicine should be ignored.

What genuinely overlaps

Nausea. Many antidepressants cause it in the first weeks, and so do these injections. Two medicines producing the same symptom is not an interaction — it is a pile-up, and it is worth staggering starts so you can tell which is which. My practical tricks for the stomach part are in side effects and how to manage them.

Appetite is the other one. Some antidepressants blunt it and some sharpen it, and a GLP-1 flattens it. If you started both close together, you may genuinely not know which is doing what.

Alcohol sits in the same pile, since it interacts with plenty of antidepressants on its own. I go through that side of it in GLP-1s and alcohol.

What to do

• Do not stop an antidepressant to start a GLP-1. Stopping abruptly has its own risks, and no label asks you to.
• Tell each prescriber about the other. They are often different people, and neither one will guess.
• If your mood drops, or you have any thought of harming yourself, contact your clinician or urgent care the same day. Do not wait for the next appointment.

The useful thing here is knowing the difference between a warning and a gap. This is a gap, and the people who can close it for you are the two prescribers who already know your history.